Jennifer A. Huntington

Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial

Marin H. Kollef, Martin Nováček, Ülo Kivistik et al. · The Lancet Infectious Diseases · 2019 · 346 citations

Pharmacy, Clinical Sciences, Infectious Diseases +16

Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic‐derived dose justification for phase 3 studies in patients with nosocomial pneumonia

Alan Xiao, Benjamin Miller, Jennifer A. Huntington et al. · The Journal of Clinical Pharmacology · 2015 · 151 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> : a pooled analysis of Phase 3 clinical trials

Myra W. Popejoy, David L. Paterson, Daniel Cloutier et al. · Journal of Antimicrobial Chemotherapy · 2016 · 123 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +14

Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects

Gurudatt Chandorkar, Jennifer A. Huntington, Mark H. Gotfried et al. · Journal of Antimicrobial Chemotherapy · 2012 · 119 citations · Full text

Medicine, Infectious Diseases, Pharmacology +15

Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial

Jennifer A. Huntington, George Sakoulas, Obiamiwe Umeh et al. · Journal of Antimicrobial Chemotherapy · 2016 · 59 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +15